2C-C

Discovery

2C-C was first synthesized by Alexander Shulgin at his private laboratory in Lafayette, California, as part of a systematic study of 4-position substituents on the 2,5-dimethoxyphenethylamine scaffold. The compound appears as entry #22 in PiHKAL: A Chemical Love Story (1991),^[3] with the synthesis likely dating to the late 1970s or early 1980s. Shulgin described two routes — direct chlorination with liquid chlorine in glacial acetic acid, and halide exchange from 2C-B via cuprous chloride — noting that handling liquid chlorine was considerably less convenient than working with bromine or iodine.^[4]

Market History

2C-C appeared on online research chemical markets in the late 1990s and early 2000s alongside the broader wave of 2C analogs entering recreational circulation. It never achieved the uptake of 2C-B or 2C-I — users seeking phenethylamine psychedelia typically preferred the more potent bromo or iodo analogs at lower doses. No clinical trials, therapeutic investigations, or institutional human studies have been conducted; the compound's entire human effects literature consists of Shulgin's self-experiments documented in PiHKAL.

Scheduling

The United States explicitly named 2C-C in the Food and Drug Administration Safety and Innovation Act (FSSIA) of July 2012, which scheduled multiple 2C analogs by name rather than relying solely on the Federal Analogue Act. Most other developed jurisdictions control 2C-C either by specific listing or through catch-all provisions targeting 2,5-dimethoxyphenethylamine derivatives.

Structural Class

2C-C belongs to the 2C family of phenethylamine psychedelics, a series built on the 2,5-dimethoxyphenethylamine backbone with variable substituents at the 4-position. In 2C-C, the 4-position substituent is chlorine, placing it alongside 2C-B (bromine), 2C-I (iodine), and 2C-F (fluorine) in the halogenated sub-series.

Within this series, halogen size at the 4-position correlates with receptor affinity and potency: iodo > bromo > chloro > fluoro.^[1] Chlorine's smaller atomic radius produces weaker hydrophobic interactions within the 5-HT₂A binding pocket, accounting for 2C-C's position at the lower end of the potency range among halogenated analogs.

Molecular Properties

The molecule comprises a phenethylamine core with methoxy groups at the 2- and 5-positions and a chlorine atom at the 4-position. The two methoxy groups provide the electron density and steric profile required for 5-HT₂A receptor recognition, while the chloro substituent modulates binding affinity and lipophilicity.

Stereochemistry

2C-C has no chirality center and exists as a single achiral compound. No stereoisomer considerations apply.

Physical Properties

The hydrochloride salt melts at 220–222°C.^[4] No published data exist for solubility, pKa, or partition coefficient. The free base is expected to be a liquid or low-melting solid based on analogy with other 2C free bases.

Mechanism of Action

2C-C acts as an agonist at serotonin 5-HT₂A and 5-HT₂C receptors — the same targets responsible for psychedelic effects across all phenethylamine hallucinogens. Binding at 5-HT₂A triggers a signaling cascade that increases excitatory neurotransmitter release onto prefrontal cortex neurons, disrupting the brain's normal sensory processing and producing perceptual distortion.^[7][8]

The psychedelic response depends specifically on one branch of the 5-HT₂A signaling pathway (Gq-coupled) rather than another (β-arrestin2), a distinction confirmed through behavioral studies in mice.^[9] In rats, 2C-C produces characteristic 5-HT₂A-mediated behaviors — wet dog shakes and back muscle contractions — completely blocked by the selective 5-HT₂A antagonist M100907, providing direct proof that its effects are 5-HT₂A-dependent.^[2]

Beyond serotonin, high-dose 2C-C also activates the brain's dopamine mesolimbic pathway. Rodent studies found increased neural activity in the nucleus accumbens and altered dopamine receptor expression in both the nucleus accumbens and prefrontal cortex.^[5] This dopaminergic recruitment may contribute to the compound's preclinical abuse signals and any stimulant-like properties at higher doses.

Pharmacokinetics

No human pharmacokinetic study has been published for 2C-C. All parameters below are inferred from structural analogy with 2C-B and class pharmacology.

Oral administration is the primary route, with onset at 20–45 minutes and full effects at approximately 1.5–2 hours.^[4][10] Total duration runs 4–8 hours, with a 2–3 hour peak.^[4][10] Intravenous administration of 20 mg produced overwhelming effects peaking within approximately 5 minutes, consistent with bypassing first-pass metabolism.^[4]

Metabolism has not been directly studied. Based on structural analogy with 2C-B, primary routes likely include breakdown by liver enzymes and monoamine oxidase.^[11]inferred 2C-C has also been identified as a metabolite of 25C-NBOMe through N-dealkylation in human liver microsomes.^[11]

Key pharmacokinetic parameters — peak blood levels, half-life, oral bioavailability, and protein binding — remain entirely uncharacterized in humans.

Where It Acts

No direct neuroimaging or electrophysiology data exist for 2C-C. The following is inferred from class-level neuroscience of serotonin 2A receptor agonist psychedelics.

5-HT₂A receptors concentrate on neurons in the prefrontal cortex. When activated, they increase excitatory signaling that disrupts normal cortical processing — the cellular trigger for perceptual distortion across all phenethylamine psychedelics.^[7][8] This cortical disruption also impairs the thalamus's ability to filter sensory input, producing the sensory flooding and pattern overlay characteristic of the 2C class.^[12]

At high doses, 2C-C additionally recruits the dopamine mesolimbic pathway. Rodent studies found increased neural activation in the nucleus accumbens and altered dopamine signaling in the prefrontal cortex^[5] — a finding that may explain preclinical indicators of abuse potential.

Theoretical Framework

The REBUS (Relaxed Beliefs Under Psychedelics) model proposes that 5-HT₂A agonists flatten the brain's predictive processing hierarchy, weakening top-down expectations and allowing more bottom-up sensory information to reach awareness. 2C-C's reportedly quiet, sedating character — unusual for the 2C class — raises the question of whether its lower potency or unique receptor interactions produce a distinct pattern of brain activity compared to more stimulating analogs.

5-HT₂A agonists are also known to promote structural brain changes (dendritic growth, new synaptic connections) through downstream signaling cascades. Whether 2C-C shares these neuroplastic properties is unknown but expected given its confirmed 5-HT₂A activity.

Toxicity

Class-level acute toxicity for 2C compounds includes agitation, hallucinations, aggression, high blood pressure, rapid heart rate, seizures, and dangerously elevated body temperature.^[14] At least five deaths have been reported across the broader 2C class — primarily involving 2C-E and 2C-T-7 — with excited delirium as a consistent finding among fatalities.^[14]

Psychological Risks

No study quantifies psychological adverse event rates for 2C-C specifically. Class-level risks for 5-HT₂A agonist psychedelics include:

• Acute psychological distress: anxiety, panic, paranoia, dysphoria, and confusion, with risk scaling with dose and vulnerability. Agitation, aggression, and dysphoria appear among 2C class intoxication presentations.^[14]
• Hallucinogen persisting perception disorder (HPPD): Persistent visual disturbances following use. No 2C-C-specific data exist.
• Psychosis precipitation: Primarily a risk for individuals with personal or family history of psychotic disorders.
• Depersonalization/derealization: Usually transient during acute effects; rarely persistent.

2C-C's reportedly milder, more sedating profile may carry lower acute distress risk compared to more stimulating analogs, though this remains unverified.

Tolerance and Dependence

Tolerance develops rapidly — within 24 hours of a single dose — through downregulation in the brain.^[19] Cross-tolerance exists between phenethylamine hallucinogens and extends to tryptamine psychedelics, with phenethylamine compounds developing tolerance more rapidly than tryptamines.^[6] Repeated use at intervals shorter than approximately 7–14 days produces diminishing effects.

No physical dependence or withdrawal has been documented for 2C-C or the 2C class. However, rodent studies found dose-dependent conditioned place preference and increased self-administration — preclinical indicators of abuse potential that challenge the conventional "non-addictive" characterization of serotonergic psychedelics.^[5] Gil-Martins et al. further examined abuse potential across the 2C and NBOMe classes.^[16]

Drug Interactions

MAOIs (dangerous): Monoamine oxidase inhibitors block the primary breakdown pathway for phenethylamines, dramatically amplifying and prolonging effects while simultaneously elevating serotonin syndrome risk through multiple converging mechanisms. safety citation needed

SSRIs/SNRIs: Long-term use typically reduces psychedelic effects through receptor downregulation. Acute high-dose combinations may increase serotonin syndrome risk.

Contraindications

Absolute

• Concurrent MAOI use: Dangerous potentiation and serotonin syndrome risk.
• Personal history of psychotic disorders: All 5-HT₂A agonists carry risk of psychosis precipitation.
• Concurrent lithium use: Seizure risk.

Relative

• Heart conditions: High blood pressure, coronary artery disease, or irregular heart rhythm increase cardiac event risk under sympathomimetic load.
• Family history of psychotic disorders: Elevated risk of psychosis precipitation.
• Bipolar disorder: Risk of manic episode.
• Liver impairment: Presumed liver metabolism; impaired clearance could prolong or intensify effects.
• Pregnancy and breastfeeding: No safety data exist.
• Concurrent tramadol use: Serotonin syndrome risk.

2C-C is controlled in most developed jurisdictions, typically captured by specific naming in scheduling legislation or by structural class provisions targeting 2,5-dimethoxyphenethylamine derivatives. It is not scheduled under the United Nations 1971 Convention on Psychotropic Substances, leaving individual nations to determine their approach.

Analog Law Considerations

Prior to the 2012 FSSIA, prosecution in the United States could be pursued under the Federal Analogue Act, which treats substances "substantially similar" to a Schedule I compound as equivalent when intended for human consumption. 2C-C's structural similarity to 2C-B (scheduled in 1995) provided a basis for such prosecution, though the Act's requirement to prove both structural and pharmacological similarity created legal ambiguity.